FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
October 19 2018 - 5:52PM
Dow Jones News
By Maria Armental
U.S. health regulators have approved Regeneron Pharmaceuticals
Inc. (REGN) and Sanofi SA's (SNY) blockbuster drug Dupixent
(dupilumab) to treat asthma.
Dupixent, which already was approved to treat eczema, is part of
a new generation of asthma treatments that are given by injection
rather than inhaled, and that act on an underlying cause of asthma
rather than treating the symptoms.
Dupixent has been approved as an add-on maintenance therapy in
patients age 12 years and older with moderate-to-severe asthma.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
October 19, 2018 18:37 ET (22:37 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
